Jyoti S. Mayadev, MD
Motivated to move the needle in cervical cancer, investigators are adding durvalumab (Imfinzi) to standard-of-care concurrent chemoradiation therapy (SOC CCRT) and brachytherapy to determine whether PD-L1 blockade is a key to improving survival outcomes.
Figure. Durvalumab and Chemoradiotherapy in Locally Advanced Cervical Cancer Phase III CALLA Trial (NCT03830866) (Click to Enlarge)
Despite the documented efficacy of EBRT and later brachytherapy, brachytherapy’s uptake is still low in cervical cancer, Mayadev said. “We’ve done a lot of research on the number of patients who get brachytherapy and found it to be around 50% in California, so we have to make a lot of strides within cervical cancer,” she added. “We need to make sure that all patients are offered brachytherapy.”
CALLA investigators will give EBRTincluding CCRT in both arms of the CALLA study. Patients randomized to the experimental arm will receive intravenous durvalumab at 1500 mg every 4 weeks for 96 weeks followed by durvalumab monotherapy for up to 24 months or until progression from the date of randomization.1
... to read the full story